Oruka COO sells 906 shares at $95.71 each

Oruka Therapeutics’ chief operating officer executed an automatic sell-to-cover of vested RSUs, with 235,478 shares remaining held directly.

Available on EDGAR 09/15/2026 - 07:12 PM EDT Accepted by SEC EDGAR 09/15/2026 - 07:11 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) reported that Chief Operating Officer Laura Lee Sandler sold 906 shares of common stock on September 15, 2026 at $95.71 per share. According to a footnote, this was an automatic, non-discretionary sell-to-cover transaction to satisfy tax withholding from vesting restricted stock units, leaving her with 235,478 shares held directly.

Insider Trade Summary

Net Seller: 906 shares

Net Sell 1 txn

Insider Sandler Laura Lee

Role Chief Operating Officer

Sold 906 shs ($87K)

Share of Position Sold 0.38%

Type	Security	Shares	Price	Value
Sale	Common Stock F1	906	$95.71	$87K

Holdings After Transaction: Common Stock — 235,478 shares (Direct)

Holdings Before and After: Common Stock, 236,384 to 235,478 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

Key Figures

Shares sold: 906 shares Sale price per share: $95.71 per share Shares held after transaction: 235,478 shares +2 more

5 metrics

Shares sold 906 shares Non-derivative common stock sale on September 15, 2026

Sale price per share $95.71 per share Price for the 906 common shares sold on September 15, 2026

Shares held after transaction 235,478 shares Direct ownership by Laura Lee Sandler following the sale

Number of sell transactions 1 transaction Single reported non-derivative sale in this Form 4

Net shares sold 906 shares Net share change across all reported transactions

Key Terms

sell-to-cover procedure, restricted stock units, tax withholding obligations

3 terms

sell-to-cover procedure financial

"automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding"

restricted stock units financial

"tax withholding obligations arising in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"procedure to satisfy tax withholding obligations arising in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who at ORKA reported a transaction in this Form 4 filing?

The filing reports a transaction by Laura Lee Sandler, who serves as Chief Operating Officer of Oruka Therapeutics, Inc. It details her holdings of the company’s common stock after the reported transaction.

What did the ORKA insider transaction on September 15, 2026 involve?

On September 15, 2026, Chief Operating Officer Laura Lee Sandler sold 906 shares of Oruka Therapeutics common stock at $95.71 per share in a non-derivative transaction reported in this Form 4.

Why were ORKA shares sold in this Form 4 transaction?

The shares were sold under Oruka Therapeutics’ automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising from the vesting of restricted stock units, according to the footnote.

How many ORKA shares does the insider hold after the reported sale?

After the reported sale, Chief Operating Officer Laura Lee Sandler directly holds 235,478 shares of Oruka Therapeutics, Inc. common stock, as stated in the Form 4 data.

Was the ORKA Form 4 transaction made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not checked. The footnote instead describes the sale as part of Oruka Therapeutics’ automatic, non-discretionary, sell-to-cover procedure for tax withholding on vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandler Laura Lee

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		S(1)		906	D	$95.71	235,478	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

	/s/ Paul Quinlan, as attorney-in-fact for Laura Sandler	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)